|Day Low/High||56.27 / 57.87|
|52 Wk Low/High||47.39 / 69.60|
These popular stocks look ready to increase their dividend payouts to shareholders in the weeks ahead.
Psalm $ -- find a dividend payer with a good chart and ignore how it makes money.
Macau reported a 7% year-over-year increase in December visits to its casinos.
Survey says: Maybe business is getting better.
If you like gambling stocks, there's an appealing option with no Macau exposure.
Wall Street scores another trifecta of record closes as a rally in the energy and tech sectors drive gains across benchmark indexes.
These names show technical characteristics of bullish or bearish reversal patterns.
U.S. stocks gained steam as the Dow Jones Industrial Average inches closer to 20,000.
The country is finally on course to approve gaming resorts this year, which is boosting casino stocks in the United States, Macau and Malaysia.
It can take many months or quarters before the market recognizes the value of a downtrodden name.
Japan appears to be close to legalizing gambling following a positive legislative committee vote on Friday.
'Quantamental' investing is the marriage between quantitative research and fundamental analysis, and it could be the next big thing in stock picking.
Macau lost one-quarter of its entire economy in 2015. Now it looks to be on steadier ground.
Las Vegas Sands and Wynn Resorts appear to be less exposed to the type of Chinese regulations that led to detention of Crown Resorts' employees.
Shares of Wynn Resorts tumbled in Friday's trading session on word of the management reshuffle in Macau.
Costco shares were among the hottest item in Wall Street shopper's carts on Friday.
Now may not be the time for gaming investors to start taking their money off the table.
The CEO answered more like a man trying to protect his job than one trying to protect his shareholders.
Luck might be turning for shareholders of Las Vegas Sands and Wynn Resorts.
The luck could be turning for shareholders in casino and resort stocks.
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
You don't need to be a master of timing to be a successful investor if you take a disciplined approach.
Good enough, tied with a good story, is pushing post-earnings bumps today.